The Amplify Seymour Cannabis ETF is positioned for upside as U.S. cannabis reclassification to Schedule III appears likely, ...

Cannabis stocks struggled on Thursday after President Donald Trump signed an executive order reclassifying marijuana as a ...

President Trump is giving most federal workers two extra days off this holiday season. In an executive order on Thursday, ...

New research reveals significant gaps between public perception and scientific evidence for medical cannabis benefits across ...

The move wouldn't legalize marijuana, but moving it from Schedule I to Schedule III would allow the FDA to study it for ...

Toronto-based Auxly (best known for its Back Forty brand) operates large-scale cultivation in Leamington, Ont., and a ...

Tilray Brands stock jumped 27.5% on December 16 following Trump's marijuana reclassification comments and analyst upgrades.

The change would not legalize the drug on the federal level, but would ease barriers on research using cannabis.

Cannabis stocks such as Canopy Growth (CGC), Tilray Brands (TLRY), and Cronos Group (CRON) are up sharply on Dec. 18 after ...

President Donald Trump has signed an executive order to amend marijuana's classification as a Schedule I federally controlled ...

Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including cannabis stocks like Tilray Brands (TLRY) and Canopy (CGC) pulling back ...

In a review of previous studies, McMaster University researchers observe a stronger signal for psilocybin as a treatment for obsessive-compulsive disorder than cannabinoids.